← Back to guidelines
Neurology15 papers

Striatonigral degeneration

Last edited: 4/15/2026

Overview

Striatonigral degeneration, also known as Olivopontocerebellar atrophy (OPCA), is a rare neurodegenerative disorder characterized by progressive motor dysfunction primarily affecting the basal ganglia and cerebellum, leading to symptoms such as parkinsonism, cerebellar ataxia, and pyramidal signs 1.

Diagnosis

  • Clinical Features: Parkinsonism, cerebellar ataxia, and pyramidal signs 1.
  • Imaging: T2-weighted MRI often shows low signal intensity and atrophy in the putamen 1.
  • Pathology: Neuropathologic confirmation includes putaminal atrophy and iron deposition in MRI low signal regions 1.
  • Management

  • No Specific Pharmacologic Treatment: Current management focuses on symptomatic relief 1.
  • Symptomatic Therapy: Use of dopaminergic agents for parkinsonian symptoms (dose specifics not provided) 1.
  • Supportive Care: Physical therapy and occupational therapy to manage motor symptoms 1.
  • Special Populations

  • No Specific Data Provided: Limited information on management in pregnancy, pediatrics, elderly, or comorbid conditions 1.
  • Key Recommendations

  • Utilize MRI with T2-weighted imaging to identify characteristic putaminal changes indicative of striatonigral degeneration (Evidence: Moderate) 1.
  • Employ symptomatic treatments such as dopaminergic agents for managing parkinsonian symptoms, though specific dosing lacks detailed guidance (Evidence: Weak) 1.
  • Focus on multidisciplinary supportive care including physical and occupational therapy to improve quality of life (Evidence: Expert opinion) 1.
  • References

    1 O'Brien C, Sung JH, McGeachie RE, Lee MC. Striatonigral degeneration: clinical, MRI, and pathologic correlation. Neurology 1990. link

    Original source

    1. [1]
      Striatonigral degeneration: clinical, MRI, and pathologic correlation.O'Brien C, Sung JH, McGeachie RE, Lee MC Neurology (1990)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG